Category: Meetings and Events

Uniform Criteria for Submission of Manuscript to the Editorial Board
[According to Guideline of BMDC]

1. Manuscript written in English on bio medical topics will be considered for publication provided these have not been published previously and are not under consideration for publication elsewhere.
2. The author should obtain written permission from appropriate authority if the manuscript contains any table, data or illustration from previously published in other Journal. The letter of permission should be submitted with manuscript to the editorial board.
3. Authors should keep one copy of their manuscript for reference & three hard copies along with softcopy should be sent to the managing editor.
4. The authors should sign a covering letter mentioning that final manuscript has been seen and approved by all authors. Relevancy and contribution of coauthors should clearly mentioned by first author. Irrelevant person or without any contribution should not be entitled as coauthors.
5. The materials submitted for publication may be in the form of an original research, review article, special article, a case report, recent advances, new techniques, books review on clinical / medical education, adverse drug reaction or a letter to the editor.
6. An author can write review article only if he / she has written a minimum of two (2) original research articles and four (4) case reports on the same topic.
7. The manuscript may be submitted by the author online following appropriate criteria as mentioned.
8. Each component of the manuscript should begin on a new page in the sequence of-

• Title page
• Abstract
• Text- Introduction, Material & Methods, Result and Discussion.
• References
• Acknowledgement

9. The title page should include the title of the paper, name of the authors, name of the departments in which they worked, email address & phone number.
10. The title should be concise, informative & self explanatory.
11. The Abstract should be structured as-introduction with objectives, materials & methods, result, discussion with conclusion including key words number of figures, tables, reference & correspondence
12. The text should be presented in the form of-

• Introduction: This should include the purpose of the article. The rational for the study or observation should be summaries. Only strictly pertinent reference should be cited. The subject should not be extensively reviewed. Data or conclusion from the work being reported should not be presented in introduction.
• Materials & methods: study design & sampling method should be mentioned. Consent from respondents / patients should be taken in the form before interview / study. All drugs & chemicals used should be identified precisely, including generic name, dose route of administration. For all quantitative measurement SI unit should be used.
• Results: This should be presented in a logical sequence in the text, tables & illustration. For Statistical Analysis standard procedure to be maintained. It should be done by a recognized statistician or subject expert related to statistics.
• Discussion: Authors comment on the result supported with contemporary references including arguments and analysis of identical work done by other workers may be elaborately discussed. A summary is not required. Brief acknowledgement may be made at the end.
• Tables: Number and titles of tables to be clearly written.
• Source of Illustrations & Figures should be mentioned.
• Abbreviations and Symbols: Use only standard abbreviations; avoid abbreviations in the title of the article.

13. References-

• Reference should be numbered in order to which they appear in the text as superscript.
• Reference should be in Vancouver style

*Authors are requested to send manuscript of article via email attached MS Word file.
Email: sadequel@yahoo.com
PDF

Editorial
ASCO 2026 Guideline: Rethinking PD-L1 Testing
*Rahman DA
Few biomarkers have travelled a more turbulent path than programmed death-ligand 1 (PD-L1). Introduced as a companion diagnostic for immune checkpoint inhibition in non-small cell lung cancer (NSCLC), PD-L1 immunohistochemistry (IHC) rapidly became one of the most consequential stains in the histopathology laboratory. Its tumour proportion score (TPS) is a continuous variable translated into clinical thresholds of 1% and 50%, on which major treatment decisions may depend.¹
The American Society of Clinical Oncology (ASCO) living guideline for stage IV NSCLC without driver alterations, published in 2026 as version 2026.3.0 and subsequently updated as 2026.3.1, redefines the place of PD-L1 in the diagnostic pathway.2,3 PD-L1 IHC remains a strong recommendation supported by high-quality evidence. For patients with TPS of 50% or higher, single-agent pembrolizumab, cemiplimab or atezolizumab remains strongly recommended; lower expression levels generally favour immunotherapy–chemotherapy combinations.² The crucial message, however, is that a validated PD-L1 assay should accompany a validated tissue and/or blood-based broad multigene panel. PD-L1 IHC alone is insufficient to guide treatment.²

This is more than a therapeutic update; it is a diagnostic reframing. PD-L1 is no longer a solitary gatekeeper but one element of an integrated biomarker assessment. Comprehensive next-generation sequencing, preferably incorporating RNA analysis for fusion detection, is emphasized, while combined tissue and plasma testing may improve the detection of actionable alterations.² A tumour with high PD-L1 expression may still harbour a targetable driver alteration that changes first-line treatment. Selecting therapy from the PD-L1 result before molecular findings are available could therefore lead to inappropriate management.

For pathologists, the guideline places tissue stewardship at the centre of practice. Many patients with advanced NSCLC are diagnosed using a small biopsy or cytology cell block. The specimen must support histological classification, PD-L1 staining and increasingly broad molecular analysis. Unnecessary immunostains, repeated sectioning and poorly coordinated send-out testing can exhaust tissue before the most clinically important investigations are completed. Reflex pathways agreed by pathologists, oncologists and molecular laboratories are therefore essential.

The requirement for a validated assay also highlights persistent concerns about PD-L1 standardisation. The Blueprint phase 2 project demonstrated broadly comparable tumour-cell staining with the 22C3, 28-8 and SP263 assays, whereas SP142 showed lower sensitivity. Interobserver reliability was strong for tumour-cell scoring but poor for immune-cell scoring.4

Interpretation remains another vulnerable step. In a multicentre study, interobserver agreement was good but imperfect at both the 1% and 50% thresholds, and brief training produced little improvement.⁵ Cases close to a cut-off are particularly difficult because weak membranous staining, necrosis, crush artefact, macrophages and scant viable tumour may alter classification. Combined positive score assessment in other tumour types introduces further variability because inflammatory cells must also be identified and counted.⁶ Laboratories should incorporate appropriate controls, competency assessment, external quality assurance and a mechanism for second review of borderline cases.
The 2026.3.1 update, which added retifanlimab plus platinum-based chemotherapy as an option for selected patients irrespective of PD-L1 level, further illustrates why PD-L1 cannot function as the sole treatment discriminator.^3,8 As therapeutic options expand, the clinical meaning of a PD-L1 category will continue to evolve. The living-guideline model is therefore appropriate, but laboratories must establish a method for rapidly translating updates into test algorithms and report comments.

For resource-constrained settings, including Bangladesh, simultaneous broad molecular testing and PD-L1 IHC may be limited by cost, access and turnaround time. ASCO 2026 does not diminish the importance of PD-L1; it places the stain in its proper context. The pathologist is now the steward of tissue and the integrator of morphology, protein expression and genomic information.
References

1. Torlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, et al. “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Mod Pathol. 2020;33(1):4–17.
2. Reuss JE, Bazhenova L, Ismaila N, Abu Rous F, Ahluwalia A, Alluri K, et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, 2026.3.0. J Clin Oncol. 2026;44(7):e56–e88.
3. Bazhenova L, Ismaila N, Durm G, Freeman-Daily J, Horinouchi H, MacVicar GR, et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, 2026.3.1. J Clin Oncol. 2026 May 26:JCO2600842.
4. Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project. J Thorac Oncol. 2018;13(9):1302–1311.
5. Cooper WA, Russell PA, Cherian M, Duhig EE, Godbolt D, Jessup PJ, et al. Intra- and interobserver reproducibility assessment of PD-L1 biomarker in non-small cell lung cancer. Clin Cancer Res. 2017;23(16):4569–4577.
6. Robert ME, Rüschoff J, Jasani B, Graham RP, Badve SS, Rodriguez-Canales J, et al. High interobserver variability among pathologists using combined positive score to evaluate PD-L1 expression in gastric, gastroesophageal junction, and esophageal adenocarcinoma. Mod Pathol. 2023;36(5):100154.
7. American Society of Clinical Oncology. Update to ASCO guideline on advanced NSCLC without driver alterations adds retifanlimab to treatment option.

* Dr. DM Arifur Rahman,  Associate Professor, Department of Histopathology, TMSS Medical College, Bogura. arifurrahmandm@gmail.com. ORCID: https://orcid.org/ 0009-0007-2493-9230
PDF

Journal of Histopathology and Cytopathology
Vol 10. Issue 1, 2026

Uniform Criteria for Submission of Manuscript to the Editorial Board

[According to Guideline of BMDC]

1. Manuscript written in English on bio medical topics will be considered for publication provided these have not been published previously and are not under consideration for publication elsewhere.
2. The author should obtain written permission from appropriate authority if the manuscript contains any table, data or illustration from previously published in other Journal. The letter of permission should be submitted with manuscript to the editorial board.
3. Authors should keep one copy of their manuscript for reference & three hard copies along with softcopy should be sent to the managing editor.
4. The authors should sign a covering letter mentioning that final manuscript has been seen and approved by all authors. Relevancy and contribution of coauthors should clearly mentioned by first author. Irrelevant person or without any contribution should not be entitled as coauthors.
5. The materials submitted for publication may be in the form of an original research, review article, special article, a case report, recent advances, new techniques, books review on clinical / medical education, adverse drug reaction or a letter to the editor.
6. An author can write review article only if he / she has written a minimum of two (2) original research articles and four (4) case reports on the same topic.
7. The manuscript may be submitted by the author online following appropriate criteria as mentioned.
8. Each component of the manuscript should begin on a new page in the sequence of-

• Title page
• Abstract
• Text- Introduction, Material & Methods, Result and Discussion.
• References
• Acknowledgement

9. The title page should include the title of the paper, name of the authors, name of the departments in which they worked, email address & phone number.
10. The title should be concise, informative & self explanatory.
11. The Abstract should be structured as-introduction with objectives, materials & methods, result, discussion with conclusion including key words number of figures, tables, reference & correspondence
12. The text should be presented in the form of-

• Introduction: This should include the purpose of the article. The rational for the study or observation should be summaries. Only strictly pertinent reference should be cited. The subject should not be extensively reviewed. Data or conclusion from the work being reported should not be presented in introduction.
• Materials & methods: study design & sampling method should be mentioned. Consent from respondents / patients should be taken in the form before interview / study. All drugs & chemicals used should be identified precisely, including generic name, dose route of administration. For all quantitative measurement SI unit should be used.
• Results: This should be presented in a logical sequence in the text, tables & illustration. For Statistical Analysis standard procedure to be maintained. It should be done by a recognized statistician or subject expert related to statistics.
• Discussion: Authors comment on the result supported with contemporary references including arguments and analysis of identical work done by other workers may be elaborately discussed. A summary is not required. Brief acknowledgement may be made at the end.
• Tables: Number and titles of tables to be clearly written.
• Source of Illustrations & Figures should be mentioned.
• Abbreviations and Symbols: Use only standard abbreviations; avoid abbreviations in the title of the article.

13. References-

• Reference should be numbered in order to which they appear in the text as superscript.
• Reference should be in Vancouver style

*Authors are requested to send manuscript of article via email attached MS Word file.

Email: sadequel@yahoo.com

Open in PDF